Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
April 29, 2000
Refill program using pharmacy student interns in a primary care clinic
M L Smith, D J Barnette, C Maffeo
Journal of Physics. Condensed Matter : an Institute of Physics Journal
|
September 20, 2014
Close encounters with DNA
C Maffeo, J Yoo, J Comer, et al.
Clinical Orthopaedics and Related Research
|
September 1, 1978
The strength of metal reinforced methylmethacrylate fixation of pathologic fractures
G J Wang, S I Reger, C Maffeo, et al.
Health Services Research
|
December 1, 1994
Results of the ACSUS for pediatric AIDS patients: utilization of services, functional status, and social severity
M C Fahs, D Waite, M Sesholtz, et al.
Journal of Community Health
|
June 1, 1996
Self-perceived unmet health care needs of persons enrolled in HIV care
K A Bonuck, P S Arno, J Green, et al.
Journal of Health Care for the Poor and Underserved
|
January 1, 1996
The impact of housing status on health care utilization among persons with HIV disease
P S Arno, K A Bonuck, J Green, et al.
Urologic Oncology
|
April 18, 2022
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial
Siamak Daneshmand, Iris S G Brummelhuis, Kamal S Pohar, et al.
The Journal of Urology
|
April 7, 2023
Reply by Authors
Mark D Tyson, David Morris, Juan Palou, et al.
The Journal of Urology
|
April 7, 2023
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study
Mark D Tyson, David Morris, Juan Palou, et al.
European Urology Open Science
|
April 8, 2024
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study
F Johannes P van Valenberg, Antoine G van der Heijden, Christopher J Cutie, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
April 29, 2000
Refill program using pharmacy student interns in a primary care clinic
M L Smith, D J Barnette, C Maffeo
Journal of Physics. Condensed Matter : an Institute of Physics Journal
|
September 20, 2014
Close encounters with DNA
C Maffeo, J Yoo, J Comer, et al.
Clinical Orthopaedics and Related Research
|
September 1, 1978
The strength of metal reinforced methylmethacrylate fixation of pathologic fractures
G J Wang, S I Reger, C Maffeo, et al.
Health Services Research
|
December 1, 1994
Results of the ACSUS for pediatric AIDS patients: utilization of services, functional status, and social severity
M C Fahs, D Waite, M Sesholtz, et al.
Journal of Community Health
|
June 1, 1996
Self-perceived unmet health care needs of persons enrolled in HIV care
K A Bonuck, P S Arno, J Green, et al.
Journal of Health Care for the Poor and Underserved
|
January 1, 1996
The impact of housing status on health care utilization among persons with HIV disease
P S Arno, K A Bonuck, J Green, et al.
Urologic Oncology
|
April 18, 2022
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial
Siamak Daneshmand, Iris S G Brummelhuis, Kamal S Pohar, et al.
The Journal of Urology
|
April 7, 2023
Reply by Authors
Mark D Tyson, David Morris, Juan Palou, et al.
The Journal of Urology
|
April 7, 2023
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study
Mark D Tyson, David Morris, Juan Palou, et al.
European Urology Open Science
|
April 8, 2024
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study
F Johannes P van Valenberg, Antoine G van der Heijden, Christopher J Cutie, et al.
Page
of 2